Vaxess Technologies

At Vaxess, we're developing a transdermal patch technology to transform home delivery of therapies like GLP-1, and vaccines (both mRNA and non-mRNA). Watch the video below to see how Vaxess's MIMIX patch and applicator is designed to be needle-free, painless for patients, and easy to administer from the comfort of their homes. https://lnkd.in/dZ3mzS4V

I was recently invited to speak at an event for Oxford Properties’ US Life Sciences team. During the fireside chat, moderated by Travis McCready,  I focused on strategy, execution, and plugging into what's going on in the scientific community.  I shared how Vaxess is working to deliver therapeutics and vaccines in a more patient-friendly way, and discussed how drug developers and device developers advance their programs from R&D through regulatory approval and commercialization. It’s important for life science startups to plan and make investments in the manufacturing process because of the time it takes to automate and scale manufacturing. As part of this planning and decision-making, office, lab, and manufacturing space becomes an integral consideration — not only because of the physical requirements for enabling R&D and manufacturing at the right scale, but also because space creates an environment that nurtures the right culture, collaboration and enablement of work whether it be at the desk, bench, or manufacturing line. To illustrate these points, I pulled back the curtain on what we’ve done at Vaxess in terms of capital planning for the scale and footprint needed for our organization. Afterwards, I had the chance to connect with many professionals at Oxford who are working with early stage companies through similar decision making like ours.  It was energizing to be able to connect what they do to the work we do at Vaxess.

Last week, I attended JP Morgan’s inaugural Innovation Economy Summit in Boston. The event’s theme was “Future of Innovation” across some of the industries Boston is strongest in: life sciences and technology. There were many inspiring speakers at the event who showcased Boston’s innovation leadership. For me, a few highlights were these talks: Pioneering the Future of Robotics, with Colin Angle, Former CEO and Co-founder of iRobot; Tye Brady, Chief Technologist at Amazon Robotics; and Amy Villeneuve, Former president and COO of Amazon Fulfillment Technologies & Robotics: One of the most fascinating points in this conversation was a reflection on how it took decades to get a robot’s body “right,” and with AI, companies are now able to get the mind “right,” too. At Vaxess, we’re very excited about what AI-powered robotic advancements mean for printing our patches at scale. Innovating Tomorrow, with serial entrepreneur and Professor at Harvard Medical School & Massachusetts Institute of Technology, George Church. I have heard Professor Church speak many times. One of the many interesting points he made last week was on failure. He believes in building libraries where only a few things need to work. Libraries are better than simulations. For him, a failure is failure to try. Endeca Effect, with Steve Papa, Andrew Lau, Adam Ferrari, and Rob Gonzalez: This was a great talk by the former leadership team at Endeca who have since gone on to start a number of successful tech companies. I really liked their point on the need to balance early stage innovation with delivery of products at scale. J.P. Morgan was also kind enough to invite me to do an interview on Vaxess as part of a series, which will be available in the coming months. I’ll share it here when it’s out.

Earlier this week, Vaxess CEO, Rachel Sha, had the chance to participate in a lively discussion on the future of vaccine development. Check out some of her takeaways, as well as the link to the full recording of the webinar below!

Vaxess was featured in this week’s Boston Globe Media article about startups working on innovative, patch-based delivery of weight-loss drugs and other therapeutics. You can read the article below, and also watch a brief video about Vaxess’s proprietary transdermal patch and applicator at  https://lnkd.in/eaYNhscx https://lnkd.in/eixrDZWs

It's been a great start to #JPM25, talking to partners and investors about the progress Vaxess has made over the last year, and what's in store for 2025 and beyond. I also brought a MIMIX transdermal patch and applicator for demonstrations.  If you'd like to watch a 30-second demo, we just posted one here — https://lnkd.in/emBEx5_4.

Vaxess CEO, Rachel Sha, shared her thoughts on the past year at Vaxess. See her full commentary below and feel free to reach out if you would like to connect at JPM next week!

Today, Vaxess is announcing that we’ve been selected to collaborate with the Novo Nordisk Bio Innovation Hub through it’s Co-Creation Greenhouse Program. Together, Vaxess and Novo Nordisk will assess the pharmacokinetic properties of administering diabetes and obesity therapeutics via Vaxess’s MIMIX transdermal patch.   Vaxess’s partnership with Novo Nordisk’s #BioInnovationHub builds on a number of 2024 advancements for the company. Recently, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Vaxess SBIR funding to test the company's MIMIX transdermal patch platform in administering GLP-1 therapies. Additionally, Vaxess raised $12 million to advance GLP-1 delivery, continue in vivo work with mRNA and expand manufacturing process capabilities in support of new partnerships. If you want to see how the Vaxess MIMIX platform works, watch the brief video. 

Vaxess Co-founder and Senior Vice President Livio Valenti recently spoke at the New Orleans BioInnovation Center. Livio gave an update on a range of use cases currently in development for the Vaxess MIMIX™ transdermal patch and applicator, from GLP-1 to mRNA vaccines. A big thank you to the New Orleans BioInnovation Center and BARDA for having Vaxess present at BioChallenge 2024!

Thank you Bio-IT World World for sharing Vaxess's NIH grant announcement! https://lnkd.in/e_XCqw-j